ArticleEuropean journal of pediatrics2008
Varicella vaccination in Europe: are we ready for a universal childhood programme?
Article in European journal of pediatrics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vaccines for preventing herpes zoster in older adults.The Cochrane database of systematic reviews · 2023Pooled it
- Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized, double-blind, non-inferiority trial.BMC pediatrics · 2016Trial
- Trial
- Varicella-Zoster Virus Prevalence among Pregnant Women: A European Epidemiological Review.Life (Basel, Switzerland) · 2023Review
- Vaccination Coverage during Childhood and Adolescence among Undergraduate Health Science Students in Greece.Children (Basel, Switzerland) · 2022Article
- Prevention of Herpes Zoster and its complications: From clinical evidence to real life experience.Human vaccines & immunotherapeutics · 2017Review
- The humanistic, economic and societal burden of herpes zoster in Europe: a critical review.BMC public health · 2015Review
- Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study.Bulletin of the World Health Organization · 2014Article
- Successes and challenges in varicella vaccine.Therapeutic advances in vaccines · 2014Review
- Computational modeling of interventions and protective thresholds to prevent disease transmission in deploying populations.Computational and mathematical methods in medicine · 2014Article
- Seroprevalence of varicella-zoster virus and predictors for seronegativity in the Amsterdam adult population.BMC infectious diseases · 2012Article
- Immune modulation during latent herpesvirus infection.Immunological reviews · 2012Review
- Vaccination coverage among adolescents and risk factors associated with incomplete immunization.European journal of pediatrics · 2011Article
- Article
- Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine.PloS one · 2010Article
- A proposal for a common nomenclature for viral clades that form the species varicella-zoster virus: summary of VZV Nomenclature Meeting 2008, Barts and the London School of Medicine and Dentistry, 24-25 July 2008.The Journal of general virology · 2010Review
- Varicella vaccination in Europe - taking the practical approach.BMC medicine · 2009Review
- Should the UK introduce varicella vaccine?Archives of disease in childhood · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Safe and effective vaccines against varicella zoster virus (VZV), the aetiological agent of varicella and shingles, have been available in Europe for the last 5-10 years. The USA has had a universal childhood vaccination policy since 1995 and this has resulted in a dramatic decrease in the incidence, morbidity and mortality related to varicella. The economic and medical burden of VZV has led to discussions regarding both the desirability and feasibility of a similar routine immunisation policy for all European children. This article examines the epidemiology of varicella in Europe and how the data emerging from the USA can be used to achieve adequate prevention of the disease. It looks into the current evidence of the health economic evaluation of universal varicella vaccination and explores the concerns surrounding such a policy, including the postulated impact on the incidence of zoster. In conclusion, the Society of Independent European Vaccination Experts (SIEVE) recommends that the immunisation of susceptible adolescents needs to be urgently implemented, in addition to the current recommendations targeting high-risk patients, their close contacts with a negative history of varicella and seronegative health-care workers. A universal policy, optimally incorporating a two-dose schedule, will be needed to finally reduce the burden of disease of varicella from a societal point of view. The SIEVE recommends the implementation of such a policy as soon as financially and practically possible.
Indexed as
Identifiers
17334784What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.